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MFiore and colleagues1 report variability in the effectiveness
of aspirin as a platelet-inhibitor measured by light-
transmission aggregometry in patients after HeartMate II
(Thoratec Corp, Pleasanton, Calif) ventricular-assist device
(VAD) implantation. Like many centers performing VAD
surgery, the investigators used a vitamin K pathway inhibi-
tor to achieve an international normalized ratio of 2 to 3
along with oral aspirin to prevent thromboembolism. The
clinical issue this study addresses is the value of platelet
light-transmission aggregometry (LTA) for assessing the
effectiveness of platelet inhibition by aspirin in patients
with an axial VAD and reflects a long-standing need.2
Resistance to aspirin and anticoagulation management in
patients with VAD are unresolved issues open to differing
interpretation.3 Several factors drive local anticoagulation
practices, including device type, pump flow, coagulation
measurements used, and past experience. Tailoring anticoa-
gulation to individual patients relies on having a measure
or measures of anticoagulant effectiveness that are highlyassociated with important patient outcomes. The clinical
problem is complicated by uncertainty regarding which ther-
apeutic targets to use to measure the multifaceted compo-
nents of the coagulation cascade in patients with VAD.4 It
is further complicated by temporal variation in coagulation
status, from immediate postoperative coagulopathy to the
procoagulant environment that is a nearly universal response
to VAD placement, in part from VAD-induced loss of high-
molecular-weight von Willebrand factor multimers.5 Indi-
vidual variability in aspirin responsiveness, anticoagulant
drug metabolism, circulating levels of coagulation factors,
platelet count and fibrinolytic activity, and etiologic cardiac
disease is seen in patients with a VAD and in cardiac popu-
lations and determines coagulation status and response to
anticoagulants and antiplatelet agents.6,7 This variation
predicts a failure of 1-size-fits-all anticoagulation strategies
and drives the need for research such as this study to nail
down this issue. Further, there is no proven advantage to
steering either an anticoagulant or a procoagulant
course—both are bad. Embolic stroke is an event feared
by patients more than death and the physician response to
bleeding is often to reduce the level of anticoagulation,
resulting in a greater incidence of embolic events.8
This study has potential value for its reliance upon LTA to
determine an appropriate long-term aspirin dosing in their
patients over a period of more than 8 months but is limited
by the small cohort size. The study observations of wide vari-
ability in aspirin dose required to achieve platelet inhibition
measured by LTA, and that the majority of patients required
aspirin doses several times higher than those required to
achieve platelet inhibition in ambulatory coronary artery dis-
ease2 are valuable. Although the authors state that adjustment
of aspirin dosing according to LTA reduced the rate ofdiovascular Surgery c Volume 148, Number 6 3125
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Mbleeding episodes, this was not the case. Eight patients
(33%) had a bleeding event and although the authors attempt
to link these events to native coagulation dysfunction, the
evidence is not convincing in my view. The observed
bleeding rate is similar to that reported in larger observa-
tional and multicenter studies,9-12 and fails to provide
convincing evidence for effectiveness of LTA-based adjust-
ment of aspirin dosing. Similarly, 3 of 24 patients experi-
enced a thromboembolic event, an event rate similar to
those seen in other HeartMate II registry studies,9-12 and
these events were seen in setting of optimal therapeutic
anticoagulation. This disconnect between adjusting aspirin
doses based on LTA measurement of platelet function, and
a failure to reduce thromboembolic or bleeding events in
their patients is disheartening and does not yet justify use
of their proposed clinical algorithm of aspirin dosing based
on LTA measurements.
Although ethical issues with randomized trials for estab-
lished clinical practices complicate research upon optimal
anticoagulant and dosing for patients with an axial-flow
VAD, there is a critical need for improvement in the still-
high rates of bleeding and thromboembolic disease. This
article1 emphasizes the need for clinical trials and a higher
standard of registries of bleeding and thromboembolic
events in patients with a VAD. To fulfill this need, bleeding
and thromboembolic outcome definitions should be more
inclusive and be specifically related to anticoagulation
status and management. Major bleeding or hemorrhagic
outcomes should to broadened from those centered around
inpatient events and transfusion,12 to include information
about anticoagulant administration and coagulation testing
before and at the time of the event, even if transfusion
or rehospitalization are not required. Similarly, when iden-
tified, thromboembolic neurologic events should be more
completely defined and provide information regarding3126 The Journal of Thoracic and Cardiovascular Suranticoagulant administration and coagulation testing.
These reporting criteria should be uniformly adopted as a
minimum standard to enhance direct comparison of study
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